Telix to Showcase Innovation in Urology at AUA Annual Meeting, including New ZIRCON Phase III Data in Very Small Renal Masses
Melbourne (Australia) | 27 April 2023
Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) in a late-breaking oral presentation at the American Urological Association (AUA) Annual Meeting being held in Chicago from 28 April to 1 May 2023.
New ZIRCON data:
Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the ZIRCON study will present new data on renal masses 2cm and smaller (a secondary endpoint).
Telix in-booth Theatre:
In addition, the Company will be presenting a series of thought leadership sessions in Telix’s in-booth theatre (at booth #1655), featuring key opinion leaders in urologic oncology and theranostics (therapeutic and diagnostic radiopharmaceuticals).
Dr Colin Hayward, Telix Chief Medical Officer, stated, “Telix’s vision in urology is to support the patient across the continuum of imaging, surgery and therapy. We are therefore pleased to be at AUA, the largest gathering of urologists worldwide, presenting further detail on the highly successful ZIRCON study, and also running our own series of lectures from key opinion leaders, including sessions on prostate-specific membrane antigen (PSMA)- and carbonic anhydrase IX- (CAIX)-targeting theranostics. We look forward to seeing you at booth #1655 where we will be delighted to introduce Telix’s deep urologic pipeline, and provide insight into the clinical utility of our approved gallium-based PSMA-PET imaging agent, Illuccix®.”
AUA presentation details are as follows (all times CDT):
Session: LBA03: Late-Breaking Abstracts III – Cancer
Title: 89Zr-DFO-girentuximab for PET/CT Imaging of Indeterminate Renal Masses – Results from Phase III ZIRCON Study
Date and Time: Sunday, April 30, 3:40pm
Presenter: Associate Professor Brian Shuch (UCLA)
Telix in-booth theatre highlights (booth #1655):
Date and Time: Friday, April 28, 9:30am
Title: New Frontiers: ZIRCON Phase Ill Study Top-Line Data
Presenter: Neeta Pandit-Taskar, MD, Memorial Sloan Kettering Cancer Center, New York
Date and Time: Friday, April 28, 12:00pm
Title: Patient Selection: What the Urologist needs to know about Lutetium PSMA Radioligand Therapy
Presenter: Pedro C. Barata, MD, MSc, University Hospitals Seidman Cancer Center, Cleveland
Date and Time: Friday, April 28, 3:00pm and Saturday, April 29, 1.30pm
Title: PSMA Image Reading for Urologists
Presenter: Jaideep S. Sohi MD, President and Founder, American Molecular Imaging
Date and Time: Sunday, April 30, 10:00am
Title: New Frontiers: Therapeutic Targeting of PSMA with Antibody vs Small Molecule
Presenter: Scott T. Tagawa, MD, MS, FASCO, FACP, Weill Cornell Medicine, New York
For full in-booth theatre listings and to secure a seat, please visit Telix’s medical education website: http://www.TelixU.com/AUA. Space is limited so early registration is recommended.